Assert-IQTM Insertable Cardiac Monitor Post Market Study
Assert-IQTM Insertable Cardiac Monitor Post Market Study
-
Clinical Trial Information
Trial Contact: Marquart, Vashnie; Ngo, George M.; Rodriguez, Jessica Marie
Trial Phone: 321-843-1037 ; 3218439657 ; 3218413270
-
IRB No: W23.208.10
Protocol Abbrev: Assert-IQ
Principal Investigator: Luis E Garcia Suero, MD
Phase: Device: Non-significant Risk
Age Group: Adult
Secondary Protocol No: ABT-CIP-10468 Ver. B
Treatment: Implantation of Assert-IQTM ICM device
Therapies Involved: Procedural
ClinicalTrials.gov ID: NCT06172699
-
Objective
To collect data to be able to evaluate the performance of the enhanced atrial fibrillation detection algorithm of the Assert-IQTM ICM device in subjects who are scheduled to receive an Assert-IQTM ICM device prior to enrollment in the study.
-
Key Eligibility
Patients must meet ALL study inclusion criteria to participate in the study.
1. Have an approved indication AND are scheduled to receive an Assert-IQTM ICM device prior to
enrollment in the study.
2. Diagnosed with symptomatic, drug-refractory paroxysmal or persistent AF prior to enrollment in
the study and scheduled to undergo a first-time atrial fibrillation ablation.
3. Have a cellular phone or the ability or willing to use a mobile transmitter that is compatible
with the myMerlin™ App and able to communicate with the Assert-IQTM ICM device. If a subject
doesn’t have a cell phone or loses their cell phone, then the site can provide a mobile transmitter
to the subject. The study will not provide cell phones.
4. Are 18 years of age or older, or of legal age to give informed consent specific to state and
national law.
5. Have the ability to provide informed consent for study participation and be willing and able to
comply with the prescribed follow-up tests and schedule of evaluations.
